All Articles

Oncologic drug pricing is being transformed with greater value in mind.

Managing the costs of oncology care while maintaining focus on outcomes of value to patients is increasingly challenging for health plans and self-insured employers who are looking to value-based agreements.

The success of pharma-sponsored oncology support service programs depends on tailoring programs to meet the needs of specific patient populations.

A number of innovative therapies in oncology have made it to market recently, with a wealth of products on the verge of approval.

In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma.

In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib.

Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved.

Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment.

The Meet-URO score combines inflammatory and clinical markers to predict response to nivolumab.

In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy.